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Objectives: Chromosome 9p21 single nucleotide
polymorphism (SNP) is a susceptibility variant for
acute myocardial infarction (AMI) in the primary
prevention setting. However, it is controversial whether
this SNP is also associated with recurrent myocardial
infarction (ReMI) in the secondary prevention setting.
The purpose of this study is to evaluate the impact of
chromosome 9p21 SNP on ReMI in patients receiving
secondary prevention programmes after AMI.
Design: A prospective observational study.
Setting: Osaka Acute Coronary Insufficiency Study
(OACIS) in Japan.
Participants: 2022 patients from the OACIS database.
Interventions: Genotyping of the 9p21 rs1333049
variant.
Primary outcome measures: ReMI event after
survival discharge for 1 year.
Results: A total of 43 ReMI occurred during the
1 year follow-up period. Although the rs1333049
C allele had an increased susceptibility to their first
AMI in an additive model when compared with 1373
healthy controls (OR 1.20, 95% CI 1.09 to 1.33,
p=2.3*10−4), patients with the CC genotype had a
lower incidence of ReMI at 1 year after discharge of
AMI (log-rank p=0.005). The adjusted HR of the
CC genotype as compared with the CG/GG genotypes
was 0.20 (0.06 to 0.65, p=0.007). Subgroup analysis
demonstrated that the association between the
rs1333049 CC genotype and a lower incidence of
1 year ReMI was common to all subgroups.
Conclusions: Homozygous carriers of the rs1333049
C allele on chromosome 9p21 showed a reduced risk
of 1 year ReMI in the contemporary percutaneous
coronary intervention era, although the C allele had
conferred susceptibility to their first AMI.
INTRODUCTION
Acute myocardial infarction (AMI) is one of
the leading causes of death and disability world-
wide.1 AMI is associated with a positive family
history as well as several traditional coronary
risk factors including diabetes, hypertension,
dyslipidemia and smoking, suggesting that the
pathogenesis of AMI has a substantial genetic
component.2 Genome-wide association studies
(GWAS) have identified several genetic loci that
confer susceptibility to AMI and coronary
artery disease (CAD) in the primary prevention
setting.3–7 Among these genetic variants, single
nucleotide polymorphisms (SNPs) on chromo-
some 9p21 are the most common and signifi-
cant susceptibility risk factors for AMI and
CAD, regardless of race.3–11 However, it remains
controversial whether chromosome 9p21 SNPs
are associated with recurrent myocardial infarc-
tion (ReMI) in patients with post-AMI receiving
the evidence-based secondary prevention
programmes.12–14
Strengths and limitations of this study
▪ This is the first study to clearly show a change
of the susceptibility risk of the 9p21 variant to
acute myocardial infarction between the primary
and secondary prevention settings in a percutan-
eous coronary intervention era.
▪ Data regarding the mechanism and culprit lesion
of remyocardial infarction were not available.
▪ Replication studies with a larger sample are
warranted to confirm our observations.
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For example, the Italian Genetic study and TexGen
registry revealed that 9p21 genetic variation was not asso-
ciated with ReMI events after early-onset myocardial infarc-
tion and acute coronary syndrome (ACS), respectively,13–14
while the Global Registry of Acute Coronary Events
(GRACE) genetic study showed that risk allele carriers of
9p21 SNPs had a higher incidence of ReMI after ACS.12
One possible explanation for this discrepancy among
these three studies is an involvement of in-hospital ReMI
as an end point. It is reported that 9p21 SNPs increase the
risk of AMI onset by promoting the development and pro-
gression of coronary plaque deposition, rather than
increasing susceptibility to plaque rupture.9–14 Thus, inclu-
sion of acute phase ReMI might have made the interpret-
ation difficult in these 9p21 variant studies, as most of the
ReMI occurring during the acute phase of AMI were most
likely caused by 9p21-independent mechanisms, such as
reocclusion of the culprit lesion and/or thrombosis.
Therefore, to simply assess the susceptibility impact of
9p21 to ReMI in the secondary prevention settings, it may
be better to include patients with post-AMI only who sur-
vived the acute stage and received the state-of-the-art sec-
ondary prevention programmes after discharge.
The aim of the present study was to investigate the sus-
ceptibility impact of 9p21 genetic variation on ReMI in
consecutive 2022 patients with a first AMI who were
registered in the Osaka Acute Coronary Insufficiency
Study (OACIS),15–19 treated with emergent percutan-
eous coronary intervention (PCI) and discharged alive.
METHODS
The OACIS
The OACIS is a multicentre, prospective observational
registry for AMI in Japan that was initiated in April 1998
among 25 collaborating hospitals. It is designed to assess
patient demographics including genomic information,
therapeutic procedures and subsequent clinical events
in patients with AMI. All study candidates were informed
about data collection, blood sampling and genotyping,
and provided written informed consent. Research cardi-
ologists and trained research nurses recorded data using
a specific reporting form. The diagnosis of AMI was
based on the WHO criteria,20 which required two of the
following three criteria to be met: (1) clinical history of
central chest pressure, pain or tightness lasting ≥30 min;
(2) ST segment elevation >0.1 mV in at least one stand-
ard and (3) a rise in serum creatinine phosphokinase
concentration to more than twice the normal laboratory
value. The OACIS is registered to the University Hospital
Medical Information Network Clinical Trials Registry
(UMIN-CTR) in Japan (ID: UMIN000004575). Other
details of the OACIS are described elsewhere.15–19
Study design
Among 10 074 consecutive patients with AMI registered
in the OACIS between April 1998 and April 2011, 2045
patients who had a first AMI, underwent emergent PCI,
survived to discharge and gave written informed consent
to the study were enrolled in this study. Exclusion cri-
teria included a history of previous myocardial infarction
or PCI, in-hospital death cases and lack of written
informed consent for genetic study and DNA sampling.
Genomic DNA was extracted from peripheral blood
samples using a commercially available kit (QIAamp
DNA Blood Midi Kit; Qiagen, Hilden, Germany).
Patients were genotyped for the rs1333049 SNP of
chromosome 9p21 using the multiplex-PCR-based
invader assay as previously described.21 We focused on
the rs1333049 because it is the most widely studied 9p21
genetic variant in the primary and secondary prevention
settings.8 10–12 14 We also confirmed that rs1333049 is in
linkage disequilibrium with other major 9p21 SNPs in
the OACIS registry (see online supplementary figure
S1). Finally, the genotyping success rate for rs1333049
was 98.9% and 2022 patients were successfully genotyped
and analysed for susceptibility to ReMI within a year
after survival discharge (figure 1). To validate the associ-
ation of the rs1333049 SNP with the first AMI, we per-
formed a case–control association study between the
present study population and healthy Japanese controls.
Control blood samples of healthy Japanese adults
(n=1373, mean age, 38.6 years old, 59% male) were
obtained from the Health Science Research Resources
Bank (Osaka, Japan). The patient backgrounds and
primary preventive medications were not adjusted in this
case–control association study in the primary prevention
setting, since these data were not available in commer-
cially obtained healthy controls and medications before
first AMI were not available in our study population in
detail.
Statistical analysis
Categorical variables were compared by the χ2 test, and
continuous variables were compared by the
Kruskal–Wallis test. The impact of the rs1333049 geno-
type on the onset of AMI was assessed in the primary
and secondary prevention settings. The impact of
rs1333049 on the onset of AMI was calculated as ORs
and 95% CIs in an additive model (OR per C allele
increase). In the secondary prevention analysis, the
Kaplan-Meier method was used to estimate event rates.
Since the Kaplan-Meier analysis revealed that the inci-
dence of ReMI differed between the CC and CG/GG
genotypes of rs1333049 (figure 2), the differences
between the CC and CG/GG genotypes were assessed by
the log-rank tests. In addition, a Cox regression model
was used to compare the 1 year prognostic impacts
between the rs1333049 CC and CG/GG genotypes
based on the estimated HRs and 95% CI. Multivariate
Cox regression analysis was performed to reduce the
confounding effects of variations in patient backgrounds
using age, gender, body mass index, ST-elevation myo-
cardial infarction (STEMI), diabetes, hypertension, dysli-
pidemia, smoking, target lesion, multivessel disease,
peak creatinine phosphokinase and prescription of ACE
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inhibitor, angiotensin receptor blocker, β-blockers,
calcium channel blockers, statins, diuretics and dual
antiplatelet agents as covariates. Hence, the final multi-
variate model included all the aforementioned covari-
ates regardless of the univariate results shown in online
supplementary table S1 because we assumed that even
non-significant differences in these covariates could be
confounders and should be adjusted. Gene–drug inter-
actions were evaluated using p for the interaction
between genotype and each drug tested. Statistical sig-
nificance was set as p<0.05 for comparison of patient
background or gene–drug interaction. Bonferroni cor-
rection for multiple testing was employed during the
secondary prevention analysis and statistical significance
was set as p<0.025 (0.05 divided by the number of inde-
pendent testing; log-rank test and multiple Cox regres-
sion analysis). All statistical analyses were performed
using SAS V.9.3 (SAS Institute Inc, Cary, North Carolina,
USA) or R software packages V.2.15.1 (R Development
Core Team).
RESULTS
Patient characteristics and medications at discharge are
shown in table 1. The median age was 65 years, 76.8%
were male and 87.7% had ST-elevation myocardial
infarction. No significant differences in patient back-
ground based on rs1333049 genotypes were detected.
In the primary prevention setting, the rs1333049 C
allele was associated with increased susceptibility to AMI
(OR 1.20 per C allele increase, 95% CI 1.09 to 1.33, p=
2.3*10−4; and OR 1.38 CC vs CG/GG, 95% CI 1.17 to
1.62, p=8.7*10−5) compared with 1373 healthy Japanese
controls (figure 3). The frequencies of the CC, CG and
GG genotypes of rs1333049 were 28.4% (574/2022),
49.3% (997/2022) and 22.3% (451/2022), respectively,
among the study population, and 22.4% (307/1373),
52.3% (718/1373) and 25.3% (348/1373), respectively,
among healthy controls.
In the secondary prevention setting, 43 ReMI (4 for
CC, 30 for CG and 9 for GG genotypes) occurred
during a 1-year follow-up period after survival discharge
Figure 1 Patient selection flow chart. AMI, acute myocardial infarction; MI, myocardial infarction; OACIS, Osaka Acute Coronary
Insufficiency Study; PCI, percutaneous coronary intervention.

























pen: first published as 10.1136/bm





for their first AMI. The Kaplan-Meier analysis revealed
that the incidence of ReMI differed between patients
with the CC and CG/GG genotypes (log-rank p=0.005;
figure 2). Multivariate Cox regression analysis revealed
that the CC genotype was associated with a lower risk of
ReMI after survival discharge compared with the CG/
GG genotypes (adjusted HR 0.20, 95% CI 0.06 to 0.65,
p=0.007). Subgroup analysis demonstrated that the asso-
ciation between the rs1333049 CC genotype and a lower
incidence of 1 year ReMI was common to all subgroups,
and no significant gene–drug interactions were detected
(figure 4).
DISCUSSION
The present study demonstrated that, in the secondary
prevention setting of AMI, homozygous carriers of the
rs1333049 risk allele (CC genotype) on chromosome
9p21 had a reduced incidence of ReMI, whereas the C
allele did have conferred susceptibility to their first AMI.
This result is of clinical importance because this is the
first study to clearly show a change in the susceptibility
risk of the 9p21 variant to AMI between before and after
the first AMI, namely, between the primary and second-
ary prevention settings.
Historically, 9p21 SNP was identified as a susceptibility
variant of CAD with GWAS using data from the Wellcome
Trust Case Control Consortium in 2007.3 Many other
GWAS have also revealed the same association between
9p21 SNP and CAD and/or myocardial infarction.3–8 In
addition, one report by Chan et al11 suggested the pres-
ence of a common pathway to develop CAD and myocar-
dial infarction via 9p21 SNP. Thus, the 9p21 SNP is now
considered as one of the most robust susceptibility var-
iants of myocardial infarction and/or CAD in the
primary prevention setting. To date, three major studies
have assessed the association between 9p21 genetic vari-
ation and ReMI rates after ACS (table 2)12–14: the Italian
genetic study and TexGen registry reported a lack of asso-
ciation with ReMI events after early-onset myocardial
infarction and ACS (fraction unknown), respectively,13–14
while the GRACE genetic study suggested a susceptibility
risk of 9p21 SNPs for ReMI after ACS (STEMI) 27.2%,
non-STEMI 43.3%, and unstable angina 29.5%).12 Since
Buysschaert et al12 also reported that the statistical signifi-
cance of the susceptibility risk of 9p21 disappeared after
full adjustment for patient background in the GRACE
genetic study, it is possible to interpret the results of these
three studies as a lack of 9p21 susceptibility to ReMI in
post-ACS patients.12–14 These findings are of clinical sig-
nificance because they suggested a modification of the
genetic risk of 9p21 by secondary prevention pro-
grammes after ACS. However, these studies are limited to
discuss modification of genetic risk with secondary pre-
vention programmes since they only examined the sus-
ceptibility impact of 9p21 SNPs to the ReMI without
comparison with that to the first AMI (ACS) in their
study cohort.
From this point of view, it is noteworthy that the
present study clearly showed a change in the 9p21 sus-
ceptibility risk to AMI between before and after the first
onset of AMI in the same population. In the present
study, the results showed that the rs1333049 C allele was
associated with onset of the first AMI (OR 1.20, 95% CI
1.09 to 1.33, p=2.3*10−4), which was consistent with the
results of several previous studies in the primary preven-
tion settings.3–8 Interestingly, however, the present study
also demonstrated that patients with the CC genotype
had a lower incidence of 1 year ReMI (adjusted HR,
0.20, 95% CI 0.06 to 0.65, p=0.007) as a novel finding.
These observations suggested that the risk of the 9p21
variant seen in the primary prevention setting of the
present study population was modified in the secondary
prevention setting. Although it is speculative, it is consid-
ered that modification of genetic risk of the rs1333049 C
allele might have unmasked the risk of the rs1333049 G
allele in the secondary prevention setting (see online
supplementary figure S2). However, it should be dis-
cussed why the 9p21 rs1333049 CC genotype was asso-
ciated with a reduced incidence of ReMI in the present
study, while not in the previous three studies.12–14 One
possible explanation for this discrepancy between the
previous studies and our current study is that we only
include patients with post-AMI who were treated with
emergent PCI on admission and survived to discharge,
whereas all previous studies included all of the patients
hospitalised for AMI or ACS and thus include ReMI
during the acute stage of ACS as an end point.
Considering that ReMI occurring during the acute stage
of ACS was most likely associated with lesion-related or
procedure-related backgrounds such as reocclusion of
the culprit lesion due to a thrombus or mechanical
acute closures rather than genetic background, inclusion
Figure 2 Kaplan–Meier estimates of remyocardial infarction
event.
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Age, years 65 (57–73) 65 (57–73) 65 (57–73) 65 (58–73) 0.986
Male, % 76.8 78.6 75.2 77.8 0.265
BMI, kg/m2 23.8 (21.9–25.9) 23.9 (21.8–25.7) 23.7 (21.8–25.8) 23.8 (22.0–26.0) 0.653
STEMI, % 87.7 88.1 86.6 89.6 0.272
Coronary risk factor
Diabetes, % 31.6 33.0 29.7 33.7 0.227
Hypertension, % 60.1 61.0 59.5 60.3 0.829
Dyslipidemia, % 46.5 43.8 47.2 48.5 0.267
Smoking, % 64.3 63.6 64.4 65.2 0.868
CAG Findings
Target lesion 0.153
Left main trunk, % 1.0 1.0 1.0 1.1
LAD, % 45.1 43.2 43.7 50.3
Diagonal branch, % 2.9 3.0 2.7 3.1
RCA, % 35.8 37.3 35.6 34.4
LCx, % 14.7 14.8 16.5 10.6
Graft, % 0.1 0.3 0.0 0.0
Unknown, % 0.4 0.3 0.4 0.4
Stenting, % 88.8 90.1 87.6 90.0 0.207
Multivessel disease, % 40.2 38.6 40.1 42.4 0.473
Peak CPK, IU/L 2269 (1027–4006) 2304 (1005–4087) 2242 (1026–4041) 2345 (1104–3882) 0.898
Medication at discharge
ACEI, % 44.6 46.2 44.2 43.5 0.650
ARB, % 40.4 38.2 41.4 41.0 0.425
Beta-blocker, % 62.0 59.9 62.5 63.4 0.466
Calcium-blocker, % 13.5 13.2 13.2 14.4 0.814
Statin, % 53.5 50.7 54.1 55.7 0.249
Diuretics, % 24.7 22.6 26.0 24.4 0.333
Dual antiplatelet, % 80.8 80.8 80.6 80.9 0.990
Categorical variables are presented as a percentage and continuous variables are presented as a median (25–75 percentiles).
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAG, coronary angiography; CPK, creatine phosphokinase; LAD, left anterior descending artery;
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of these ReMI might have made the interpretation of
the results difficult in the previous studies. In addition,
limiting patient selection to those treated with primary
PCI for the first AMI in the present study might have
clearly elucidated the 9p21-treated susceptibility to ReMI
in the secondary prevention cohort.
The 9p21 locus is adjacent to the tumour suppressor
genes CDKN2A and CDKN2B.8 Although the mechan-
ism by which variation in the 9p21 locus increases AMI
susceptibility in the primary prevention setting remains
unclear,8 the evidence-based secondary prevention pro-
grammes might have masked the susceptibility risk of
the 9p21 rs1333049 C allelle to ReMI after ACS in the
present study (figure 2), possibly via stabilising coronary
plaques.9–14 22–23 Indeed, Do et al24 reported that the
impact of 9p21 genetic variation can be modified by
increasing the dietary intake of vegetables, suggesting a
role of secondary prevention programmes including
dietary practice. Thus, further studies are warranted to
investigate whether and how secondary prevention pro-
grammes with evidence-based medication and lifestyle
modification can reduce the risk of ReMI in patients
with 9p21 genetic variants in the near future. In particu-
lar, the potential interaction of the rs1333049 SNP with
secondary prevention medications warrants further
investigation, because gene–drug interactions have
already been detected in cardiovascular patients treated
with warfarin, clopidogrel and statin.25–27
The present study has several limitations that warrant
mention. First, since our study population only consisted
of patients who provided written informed consent at sur-
vival discharge, there may have been selection bias as well
as a survival bias since high-risk patients carrying the C
allele might have died more frequently than patients with
the GG genotype during hospitalisation. Second, the
number of ReMI was relatively small and our study lacked
a replication cohort to validate our observations.
Therefore, replication studies with a larger sample are war-
ranted to confirm our observations. However, it is often
difficult to have a validation cohort in a prospective
Figure 3 Impact of the rs1333049 genotype on onset and
1 year remyocardial infarction. AMI, acute myocardial
infarction; (CC vs CG/GG); (C vs G per allele); ReMI,
recurrence of myocardial infarction.
Figure 4 Subgroup analysis of
the impact of rs1333049
genotype on 1 year remyocardial
infarction rate. ACEI, ACE
inhibitor; ARB, angiotensin
receptor blocker; DAPT, dual
antiplatelet therapy; NA, not
assessed due to the insufficient
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observational study design.28 Indeed, all studies presented
in table 2 did not include a replication cohort. Third,
therapeutic regiment of AMI varied across the study
period. Fourth, data regarding the mechanism and culprit
lesion of ReMI were not available. Since ReMI can occur
through a variety of mechanisms such as acute stent
thrombosis of the culprit lesion, excessive intimal prolifer-
ation of stented vessels, and plaque rupture of new athero-
sclerotic lesions, a detailed analysis for the mechanism of
ReMI is ideal. Fifth, patient backgrounds and primary pre-
ventive medications were not adjusted in the case–control
association study in the primary prevention setting. Finally,
it is possible that unmeasured confounding factors influ-
enced the study outcomes due to the inherent nature of
observational registry. The data should be interpreted
within the context of these potential limitations.
CONCLUSIONS
We demonstrated that homozygous carriers of the AMI
susceptibility variant rs1333049 SNP C allele on chromo-
some 9p21 showed a reduced risk of 1 year ReMI after
survival discharge, suggesting a modification of genetic
susceptibility of AMI with secondary prevention
programmes.
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Table 2 Summary of studies examining the association between 9p21 variants and remyocardial infarction events after
acute coronary syndrome
OACIS registry GRACE genetic study
Italian genetic
study TexGen registry
Reference – 12 13 14
Year – 2010 2011 2012
SNP rs1333049 rs1333049 rs1333040 rs1333049
Pt number 2022 2942 1508 2067
Design Prospective Prospective Prospective Prospective
Follow-up 1 year 6 months 9.95 years 3.2 years








Early-onset MI ACS (fraction
unknown)
PCI 100% 47.5% 0% 63.6%






Conclusion Low event rate with
homozygous carriers of risk
allele
High event rate with risk
allele carriers (univariate)
No association No association
Replication None None None None
ACS, acute coronary syndrome; CAD, coronary artery disease; DES, drug-eluting stent; GRACE, Global Registry of Acute Coronary Events;
MI, myocardial infarction; OACIS, Osaka Acute Coronary Insufficiency Study; PCI, percutaneous coronary intervention; Pt, participants; ReMI,
recurrence of myocardial infarction; STEMI, ST-elevation myocardial infarction; UA, unstable angina.
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